Sunday 18 October 2026
Export SRZN’s income statement to Excel — free account
Surrozen, Inc.
SRZN Healthcare Biotechnology
Surrozen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 67.4% from fiscal 2024. In the quarter to June 2026, revenue grew 408.7%, EPS grew 7.84% and free cash flow fell 21.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
23.44
1.63
−6.50%
Follow SRZN
| Dec '17 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 | — | 0.00 | 0.00 |
P/S ratio |
— | — | — | 0.00 | — | 0.00 | 48.61 |
Altman Z-Score |
— | — | — | (2.43) | — | (8.61) | (7.50) |
P/FCF ratio |
— | — | — | 0.00 | — | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | 1.35 | — | (18.77) | (15.54) |
P/Operating CF |
— | — | — | (95.04) | — | 12.09 | (29.08) |
Beneish M-Score |
— | — | — | — | — | — | (14.31) |
P/B ratio |
— | — | — | 0.26 | — | 0.00 | 0.00 |
Price to Tangible BV |
— | — | — | 0.26 | — | 0.00 | 0.00 |
EV/Sales |
— | — | — | 0.00 | — | 0.00 | 22.94 |
EV/EBITDA |
— | — | — | 1.03 | — | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | 1.28 | — | (0.43) | (2.64) |
EV/FCF |
— | — | — | 1.26 | — | (0.43) | (2.63) |
Quick Ratio |
— | 6.76 | 7.50 | 8.00 | 5.34 | 5.07 | 9.01 |
Current Ratio |
— | 6.90 | 7.75 | 8.35 | 5.75 | 5.32 | 9.22 |
Net Debt/EBITDA |
— | 1.59 | 1.95 | 1.79 | 0.81 | 1.43 | 2.15 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.11 | 0.00 | 0.23 | 0.05 |
Operating CF/Net income |
— | 0.89 | 0.89 | 1.23 | 0.94 | 0.28 | 0.13 |
Capex/Depreciation |
— | (0.45) | (0.58) | (0.35) | (0.34) | (0.02) | (0.24) |
| — | (32.72%) | (69.62%) | (38.78%) | (75.55%) | (767.91%) | 231.45% | |
| — | (105.43%) | (54.86%) | (31.78%) | (63.52%) | (134.46%) | (328.86%) | |
ROIC |
— | 0.00% | (433.10%) | (17,001.15%) | (1,512.29%) | 0.00% | 0.00% |
Return on Tangible Assets |
— | (67.07%) | (56.68%) | (47.88%) | (119.72%) | (197.53%) | (294.93%) |
Average Days of Receivables |
— | — | — | 57.76 | 0.00 | 87.05 | 21.83 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 296.10% | 0.00% | 198.33% | 844.55% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 158.61% | 0.00% | 141.36% | 466.03% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 36.14% | 0.00% | 38.61% | 110.30% |
Graham Net Nets |
— | — | — | 3.48 | — | (0.73) | (1.15) |
Graham Number |
— | — | — | 0.00 | — | 59.75 | 137.30 |
Earnings Yield |
— | — | — | (185.18%) | — | (151.71%) | (147.65%) |
Free Cash Flow Yield |
— | — | — | (230.31%) | — | (41.94%) | (17.97%) |
Revenue per Share |
— | 0.00 | 0.00 | 5.40 | 0.00 | 3.63 | 0.47 |
Operating CF per Share |
— | (27.31) | (29.64) | (19.08) | (20.00) | (6.01) | (4.04) |
Capex per Share |
— | (0.82) | (0.77) | (0.31) | (0.20) | (0.01) | (0.02) |
Free Cash Flow per Share |
— | (28.13) | (30.41) | (19.39) | (20.20) | (6.02) | (4.06) |
Cash per Share |
— | 46.16 | 61.85 | 32.77 | 17.86 | 11.78 | 11.93 |
Shareholders Equity per Share |
— | 44.39 | 66.61 | 32.84 | 18.80 | (7.29) | (25.11) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 44.39 | 66.61 | 32.84 | 18.80 | (7.29) | (25.11) |
Free Cash Flow |
— | (29.97) | (50.08) | (44.87) | (40.76) | (17.65) | (30.37) |
Working Capital |
— | 42.95 | 91.62 | 71.57 | 33.98 | 31.62 | 81.63 |
Capital Expenditures |
— | (0.87) | (1.27) | (0.73) | (0.40) | (0.03) | (0.13) |
Net Current Asset Value |
— | 35.46 | 77.72 | 67.87 | 32.99 | (30.91) | (194.93) |
EV/EBIT |
— | — | — | 1.27 | — | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.00 | 0.06 | 0.00 | 0.00 | 0.04 |
Price to Operating Income |
— | — | — | 0.00 | — | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
— | 0.33 | 0.45 | 0.57 | 0.60 | 2.57 | 1.24 |
Cash ROIC |
— | (31.07%) | (23.67%) | (29.55%) | (55.10%) | (133.89%) | 30.83% |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 4.54 | 2.53 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | — | 2.07 | 2.35 | 1.37 |
Average Payables |
— | 2.25 | 2.25 | 1.69 | 0.59 | 0.42 | 0.52 |
Average Assets |
— | 31.03 | 99.62 | 113.30 | 67.76 | 47.27 | 73.60 |
Average Common Equity |
— | 99.98 | 78.50 | 92.85 | 56.97 | 8.28 | (104.57) |
Columns are period end dates